ReviewCancers2017
Secondary Intracranial Tumors Following Radiotherapy for Pituitary Adenomas: A Systematic Review.
Review in Cancers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Excess mortality in radiotherapy-treated pituitary adenoma patients: 50-year follow-up.Journal of the Endocrine Society · 2026Article
- Article
- Understanding the Radiobiology of Central Nervous System Diseases in the Golden Age of Radiosurgery-Does It Matter?Brain sciences · 2025Review
- Malignant transformation of pituitary adenoma to carcinosarcoma: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- The Neural Frontier of Future Medical Imaging: A Review of Deep Learning for Brain Tumor Detection.Journal of imaging · 2024Review
- Article
- Harnessing exosomes as cancer biomarkers in clinical oncology.Cancer cell international · 2024Review
- Case report: Spindle cell sarcoma and pituitary adenoma in the sella region-a rare collision tumor.Frontiers in oncology · 2024Article
- Radiation-induced Undifferentiated Malignant Pituitary Tumor After 5 Years of Treatment for Cushing Disease.JCEM case reports · 2023Article
- Radiation-Induced Papillary Meningioma: A Case Report.Asian journal of neurosurgery · 2022Article
- MicroRNA-206 relieves irradiation-induced neuroinflammation by regulating connexin 43.Experimental and therapeutic medicine · 2021Article
- Article
- Gamma Knife radiosurgery as the initial treatment for elderly patients with nonfunctioning pituitary adenomas.Journal of neuro-oncology · 2021Article
- Radiation-induced intracranial osteosarcoma of the anterior skull base after treatment of esthesioneuroblastoma.BMJ case reports · 2021Article
- The Impact of Radiotherapy on the Incidence of Secondary Malignancies: A Pan-Cancer Study in the US SEER Cancer Registries.Current oncology (Toronto, Ont.) · 2021Article
- The influence of radiotherapy techniques on the plan quality and on the risk of secondary tumors in patients with pituitary adenoma.BMC cancer · 2020Article
- Fatal high-grade skull osteosarcoma 30 years following radiotherapy for Cushing's disease.Endocrinology, diabetes & metabolism case reports · 2020Article
- Article
- Identification of a miRNA-mRNA network associated with lymph node metastasis in colorectal cancer.Oncology letters · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary adenomas are often treated with radiotherapy for the management of tumor progression or recurrence. Despite the improvement in cure rates, patients treated by radiotherapy are at risk of development of secondary malignancies. We conducted a comprehensive literature review of the secondary intracranial tumors that occurred following radiotherapy to pituitary adenomas to obtain clinicopathological characteristics. The analysis included 48 neuroepithelial tumors, 37 meningiomas, and 52 sarcomas which were published between 1959-2017, although data is missing regarding overall survival and type of irradiation in a significant proportion of the reports. The average onset age for the pituitary adenoma was 37.2 ± 14.4 years and the average latency period before the diagnosis of the secondary tumor was 15.2 ± 8.7 years. Radiotherapy was administered in pituitary adenomas at an average dose of 52.0 ± 19.5 Gy. The distribution of pituitary adenomas according to their function was prolactinoma in 10 (7.2%) cases, acromegaly in 37 (27.0%) cases, Cushing disease in 4 (2.9%) cases, PRL+GH in 1 (0.7%) case, non-functioning adenoma in 57 (41.6%) cases. Irradiation technique delivered was lateral opposing field in 23 (16.7%) cases, 3 or 4 field technique in 27 (19.6%) cases, rotation technique in 10 (7.2%) cases, radio surgery in 6 (4.3%) cases. Most of the glioma or sarcoma had been generated after lateral opposing field or 3/4 field technique. Fibrosarcomas were predominant before 1979 (p < 0.0001). The median overall survival time for all neuroepithelial tumors was 11 months (95% confidence intervals (CI), 3-14). Patients with gliomas treated with radiotherapy exhibited a non-significant positive trend with longer overall survival. The median overall survival time for sarcoma cases was 6 months (95% CI, 1.5-9). The median survival time in patients with radiation and/or chemotherapy for sarcomas exhibited a non-significant positive trend with longer overall survival. In patients treated with radiotherapy for pituitary adenomas, the risk of secondary tumor incidence warrants a longer follow up period. Moreover, radiation and/or chemotherapy should be considered in cases of secondary glioma or sarcoma following radiotherapy to the pituitary adenomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.